down arrow

Athira Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04746L1044
USD
6.72
2.58 (62.52%)

Dec 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.548.36

52 Week

2.198.36
Valuation
Technical
Day's Volume

CASH

60.47 M

Shareholding (Mar 2025)

FII

2.29%

Held by 16 FIIs

DII

79.13%

Held by 21 DIIs

Promoter

0.47%

How big is Athira Pharma, Inc.?

22-Jun-2025

As of Jun 18, Athira Pharma, Inc. has a market capitalization of 12.57 million, with net sales of 0.00 million and a net profit of -79.74 million over the latest four quarters. Shareholder's funds are 44.84 million and total assets are 58.78 million.

As of Jun 18, Athira Pharma, Inc. has a market capitalization of 12.57 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -79.74 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 44.84 million and Total Assets at 58.78 million.

Read More

What does Athira Pharma, Inc. do?

22-Jun-2025

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration. It has a market cap of $12.57 million and reported a net profit loss of $9 million as of March 2025.

Overview: <BR>Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 12.57 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.97 <BR>Return on Equity: -202.57% <BR>Price to Book: 0.34<BR><BR>Contact Details: <BR>Address: 18706 North Creek Parkway, Suite 104, Box 352141 BOTHELL WA : 98011 <BR>Tel: 1 206 2218112 <BR>Fax: 1 302 6365454 <BR>Website: https://www.athira.com/

Read More

Who are in the management team of Athira Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Athira Pharma, Inc. includes Ms. Kelly Romano, who serves as a Director.

As of March 2022, the management team of Athira Pharma, Inc. includes Ms. Kelly Romano, who serves as a Director.

Read More

Is Athira Pharma, Inc. technically bullish or bearish?

25-Jun-2025

As of June 9, 2025, the technical trend has shifted to mildly bearish, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.

As of 9 June 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish outlook and the weekly Bollinger Bands showing a mildly bearish trend. While the weekly MACD and KST are mildly bullish, they are overshadowed by the bearish signals from the daily moving averages and Bollinger Bands. The overall sentiment reflects a lack of strong bullish momentum, with the stock's performance significantly lagging behind the S&P 500 over various time frames.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 15 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-174.22%

stock-summary
Price to Book

0.47

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
75.46%
0%
75.46%
6 Months
116.77%
0%
116.77%
1 Year
23.64%
0%
23.64%
2 Years
-68.6%
0%
-68.6%
3 Years
112.66%
0%
112.66%
4 Years
-94.53%
0%
-94.53%
5 Years
-97.83%
0%
-97.83%

Athira Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-9.16%
EBIT to Interest (avg)
-77.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.97
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
68.36%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.38
EV to EBIT
0.28
EV to EBITDA
0.29
EV to Capital Employed
-20.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-202.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 14 Schemes (18.12%)

Foreign Institutions

Held by 16 Foreign Institutions (2.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 73.98% vs 9.12% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.10",
          "val2": "-27.80",
          "chgp": "74.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.00",
          "val2": "-26.90",
          "chgp": "73.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.67% vs -23.12% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-95.80",
          "val2": "-126.10",
          "chgp": "24.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.10",
          "val2": "1.60",
          "chgp": "-356.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-96.90",
          "val2": "-117.70",
          "chgp": "17.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.10
-27.80
74.46%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.00
-26.90
73.98%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 73.98% vs 9.12% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-95.80
-126.10
24.03%
Interest
0.00
0.00
Exceptional Items
-4.10
1.60
-356.25%
Consolidate Net Profit
-96.90
-117.70
17.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.67% vs -23.12% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Athira Pharma, Inc. stock-summary
stock-summary
Athira Pharma, Inc.
Pharmaceuticals & Biotechnology
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
Company Coordinates stock-summary
Company Details
18706 North Creek Parkway, Suite 104, Box 352141 BOTHELL WA : 98011
stock-summary
Tel: 1 206 2218112
stock-summary
https://www.athira.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."